Works matching IS 15228517 AND DT 2020 AND VI 22 AND IP 12
Results: 27
Highlights from the Literature.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1725, doi. 10.1093/neuonc/noaa246
- By:
- Publication type:
- Article
Forthcoming Meetings.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1895, doi. 10.1093/neuonc/noaa245
- Publication type:
- Article
Radiotherapy innovations to optimize brain metastases control.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1715, doi. 10.1093/neuonc/noaa244
- By:
- Publication type:
- Article
The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returns.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1721, doi. 10.1093/neuonc/noaa243
- By:
- Publication type:
- Article
Mapping uncharted territory: a gene expression signature for precision glioblastoma therapeutics.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1713, doi. 10.1093/neuonc/noaa242
- By:
- Publication type:
- Article
Young children with medulloblastoma: important open questions and the high-risk dilemma.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1723, doi. 10.1093/neuonc/noaa241
- By:
- Publication type:
- Article
Penetrating the brain tumor space with DNA damage response inhibitors.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1718, doi. 10.1093/neuonc/noaa228
- By:
- Publication type:
- Article
Reply to: "Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less?".
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1889, doi. 10.1093/neuonc/noaa209
- By:
- Publication type:
- Article
Reply to: "Call of duty: neuro-oncology outpatient management during the COVID-19 pandemic in Milan, Italy".
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1893, doi. 10.1093/neuonc/noaa203
- By:
- Publication type:
- Article
Extended adjuvant temozolomide in newly diagnosed glioblastoma: is more less? Comment on "A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)".
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1887, doi. 10.1093/neuonc/noaa194
- By:
- Publication type:
- Article
Executive summary from American Radium Society's appropriate use criteria on neurocognition after stereotactic radiosurgery for multiple brain metastases.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1728, doi. 10.1093/neuonc/noaa192
- By:
- Publication type:
- Article
Letter regarding "Extensive brainstem infiltration, not mass effect, is a common feature of end-stage cerebral glioblastomas".
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1882, doi. 10.1093/neuonc/noaa186
- By:
- Publication type:
- Article
Corrigendum to: Recycling drug screen repurposes hydroxyurea as a sensitizer of glioblastomas to temozolomide targeting de novo DNA synthesis, irrespective of molecular subtype.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1894, doi. 10.1093/neuonc/noaa166
- By:
- Publication type:
- Article
Call of duty: neuro-oncology outpatient management during the COVID-19 pandemic in Milan, Italy.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1891, doi. 10.1093/neuonc/noaa164
- By:
- Publication type:
- Article
Delayed referral of pediatric brain tumors during COVID-19 pandemic.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1884, doi. 10.1093/neuonc/noaa159
- By:
- Publication type:
- Article
Development of a gene expression–based prognostic signature for IDH wild-type glioblastoma.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1742, doi. 10.1093/neuonc/noaa157
- By:
- Publication type:
- Article
Protein sumoylation with SUMO1 promoted by Pin1 in glioma stem cells augments glioblastoma malignancy.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1809, doi. 10.1093/neuonc/noaa150
- By:
- Publication type:
- Article
TRIM24 promotes stemness and invasiveness of glioblastoma cells via activating Sox2 expression.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1797, doi. 10.1093/neuonc/noaa138
- By:
- Publication type:
- Article
Inhibition of SETMAR–H3K36me2–NHEJ repair axis in residual disease cells prevents glioblastoma recurrence.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1785, doi. 10.1093/neuonc/noaa128
- By:
- Publication type:
- Article
Deregulated expression of the imprinted DLK1-DIO3 region in glioblastoma stemlike cells: tumor suppressor role of lncRNA MEG3.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1771, doi. 10.1093/neuonc/noaa127
- By:
- Publication type:
- Article
Ad-CD40L mobilizes CD4 T cells for the treatment of brainstem tumors.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1757, doi. 10.1093/neuonc/noaa126
- By:
- Publication type:
- Article
Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1873, doi. 10.1093/neuonc/noaa122
- By:
- Publication type:
- Article
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01).
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1851, doi. 10.1093/neuonc/noaa107
- By:
- Publication type:
- Article
Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1822, doi. 10.1093/neuonc/noaa105
- By:
- Publication type:
- Article
Excellent outcome of young children with nodular desmoplastic medulloblastoma treated on "Head Start" III: a multi-institutional, prospective clinical trial.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1862, doi. 10.1093/neuonc/noaa102
- By:
- Publication type:
- Article
Phase II trial of hippocampal-sparing whole brain irradiation with simultaneous integrated boost for metastatic cancer.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1831, doi. 10.1093/neuonc/noaa092
- By:
- Publication type:
- Article
Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.
- Published in:
- Neuro-Oncology, 2020, v. 22, n. 12, p. 1840, doi. 10.1093/neuonc/noaa104
- By:
- Publication type:
- Article